Form 4: Catalyst Pharmaceuticals Executive Exercises Stock Options

Steve Miller, Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, exercised stock options and received 14,000 shares of common stock on December 27, 2024.

Summary

• On December 27, 2024, Steve Miller, the Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, exercised restricted stock units.
• This transaction resulted in the acquisition of 14,000 shares of common stock.
• Following the transaction, Miller directly owns 935,996 shares of common stock and 1,538,176 derivative securities.
• The restricted stock units vest in three equal tranches annually on December 27, 2023, December 27, 2024, and December 27, 2025.
• Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard insider transaction disclosure. It doesn't inherently indicate positive or negative news about the company's performance.

Positives

• The executive's decision to exercise stock options could be interpreted as a positive signal, reflecting confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it slightly increases the number of outstanding shares.

Key Dates